Prudential Financial Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Prudential Financial Inc trades at $114.45 (market cap $39.15B), while Vir Biotechnology Inc. Common Stock trades at $10.49 (market cap $1.76B). The key difference: Prudential Financial Inc is far larger — about 22.2× Vir Biotechnology Inc. Common Stock's market cap, and Prudential Financial Inc pays a 4.93% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential Financial Inc for 146 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| PRU | VIR | |
|---|---|---|
Market Cap | $39.15B | $1.76B |
Volume | 1,633,697 | 2,764,948 |
Sector | Financials | Health |
52-Week High | $125.13 | $11.78 |
52-Week Low | $92.00 | $5.12 |
Typical Hold Time | 146 Days | 0 Days |
Enterprise Value | $67.93B | $1.32B |
Dividend Yield | 4.93% | — |
Signals from Pluang's Aura AI — not financial advice
Prudential Financial (PRU) trades at $113.41, showing minimal daily movement with a 0.02% gain. The stock presents mixed signals with bearish technical indicators but solid fundamentals including a P/E of 10.29 and ROE of 12.46%. Recent earnings show two consecutive beats, while the company executes strategic initiatives including a $185 million Alexforbes stake sale and rebranding to Prudential Wealth Advisors.
PRU offers value investor appeal with attractive valuation metrics and dividend income, though analyst consensus leans heavily toward Hold (67.57%) with a $105.56 price target below current levels. Key risks include execution of the $3 billion capital rotation plan and sensitivity to interest rate changes, while opportunities exist in annuity market growth and cost reduction initiatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →